CLOs on the Move

Omega Therapeutics

www.omegatherapeutics.com

 
Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism`s life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega`s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Ling Zeng
Chief Legal and Administrative Officer Profile
Jeffrey Kopacz
Vice President, Intellectual Property Profile

Similar Companies

EntreMed

EntreMed is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kirin Pharma USA

Kirin Pharma USA is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Demetrix

Nature is a rich source of ingredients. Inconsistent quality and supply, along with inaccessibility of rare substances, mean it`s not always an ideal source to meet the world`s needs.

Cell Biosciences Inc

Cell Biosciences Inc is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioTime

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.